LeMaitre dips on guiding below EPS and revenue

LeMaitre (LMAT) -4% on reporting Q2 EPS of $0.27 lacking consensus by 1 cent.

Gross sales of $39.6M, +10% was pushed by Artegraft, XenoSure, carotid shunts, allografts and valvulotomes. By geography, gross sales have been pushed by the Americas (+12%), EMEA (+6%) and APAC (+9%).

Gross margin declined to 65.6% vs. 66.3% in Q1 2021 on account of foreign exchange and hiring was up 49% from a 12 months in the past.

The corporate introduced a quarterly dividend of $0.125/share of frequent inventory. The dividend might be paid on June 2, 2022 to shareholders of document on Could 17, 2022.

In April, 2022, the corporate dedicated to the closure of its St. Etienne, France manufacturing facility leading to ~$3.1M of particular fees in 2022, and the closure is estimated to extend annual working revenue by ~$1M, starting in 2023.

Q2 Steering: Gross sales of $40M-$42.1M vs. $42.54M consensus, EPS of $0.29-$0.35 vs. $0.38 consensus.

FY22 Steering: Gross sales of $160M-$164M vs. $164.73M consensus, EPS of $1.21-$1.31 vs. $1.38 consensus.

Barrington lowered PT to $50 from $54.

Press Launch